|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD, Fuchs HE and Jemal
A: Cancer statistics, 2022. CA Cancer J Clin. 72:7–33. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Benard VB, Watson M, Saraiya M, Harewood
R, Townsend JS, Stroup AM, Weir HK and Allemani C: Cervical cancer
survival in the United States by race and stage (2001–2009):
Findings from the CONCORD-2 study. Cancer. 123 (Suppl
24):S5119–S5137. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Corley SM, Mendoza-Reinoso V, Giles N,
Singer ES, Common JE, Wilkins MR and Beverdam A: Plau and Tgfbr3
are YAP-regulated genes that promote keratinocyte proliferation.
Cell Death Dis. 9:11062018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Peng W, Wu Y, Zhang G, Zhu W, Chang M,
Rouzi A, Jiang W, tong J, Wang Q, Liu J, et al: GLIPR1 protects
against cigarette smoke-induced airway inflammation via PLAU/EGFR
signaling. Int J Chron Obstruct Pulmon Dis. 16:2817–2832. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Buckley BJ, Ali U, Kelso MJ and Ranson M:
The urokinase plasminogen activation system in rheumatoid
arthritis: Pathophysiological roles and prospective therapeutic
targets. Curr Drug Targets. 20:970–981. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Huo Z, Li X, Zhou J, Fan Y, Wang Z and
Zhang Z: Hypomethylation and downregulation of miR-23b-3p are
associated with upregulated PLAU: A diagnostic and prognostic
biomarker in head and neck squamous cell carcinoma. Cancer Cell
Int. 21:5642021. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sun J, Zhou F, Xue J, Ji C, Qu Y and Pan
Y: Long non-coding RNA TRPM2-AS regulates microRNA miR-138-5p and
PLAU (plasminogen activator, urokinase) to promote the progression
of gastric adenocarcinoma. Bioengineered. 12:9753–9765. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Moquet-Torcy G, Tolza C, Piechaczyk M and
Jariel-Encontre I: Transcriptional complexity and roles of
Fra-1/AP-1 at the uPA/Plau locus in aggressive breast cancer.
Nucleic Acids Res. 42:11011–11024. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chen G, Sun J, Xie M, Yu S, Tang Q and
Chen L: PLAU promotes cell proliferation and epithelial-mesenchymal
transition in head and neck squamous cell carcinoma. Front Genet.
12:6518822021. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang S, Jiang L, Han Y, Chew SH, Ohara Y,
Akatsuka S, Weng L, Kawaguchi K, Fukui T, Sekido Y, et al:
Urokinase-type plasminogen activator receptor promotes
proliferation and invasion with reduced cisplatin sensitivity in
malignant mesothelioma. Oncotarget. 7:69565–69578. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zou B, Li J, Xu K, Liu JL, Yuan DY, Meng Z
and Zhang B: Identification of key candidate genes and pathways in
oral squamous cell carcinoma by integrated bioinformatics analysis.
Exp Ther Med. 17:4089–4099. 2019.PubMed/NCBI
|
|
13
|
Wu M, Wei B, Duan SL, Liu M, Ou-Yang DJ,
Huang P and Chang S: Methylation-driven gene PLAU as a potential
prognostic marker for differential thyroid carcinoma. Front Cell
Dev Biol. 10:8194842022. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang H, Lu L, Liang X and Chen Y:
Identification of prognostic genes in the pancreatic adenocarcinoma
immune microenvironment by integrated bioinformatics analysis.
Cancer Immunol Immunother. 71:1757–1769. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Daneri-Navarro A, Macias-Lopez G,
Oceguera-Villanueva A, Del Toro-Arreola S, Bravo-Cuellar A,
Perez-Montfort R and Orbach-Arbouys S: Urokinase-type plasminogen
activator and plasminogen activator inhibitors (PAI-1 and PAI-2) in
extracts of invasive cervical carcinoma and precursor lesions. Eur
J Cancer. 34:566–569. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kobayashi H, Fujishiro S and Terao T:
Impact of urokinase-type plasminogen activator and its inhibitor
type 1 on prognosis in cervical cancer of the uterus. Cancer Res.
54:6539–6548. 1994.PubMed/NCBI
|
|
17
|
Koelbl H, Kirchheimer JC, Tatra G, Christ
G and Binder BR: Increased plasma levels of urokinase-type
plasminogen activator with endometrial and cervical cancer. Obstet
Gynecol. 72:252–256. 1988.PubMed/NCBI
|
|
18
|
Kou XX, Hao T, Meng Z, Zhou YH and Gan YH:
Acetylated Sp1 inhibits PTEN expression through binding to PTEN
core promoter and recruitment of HDAC1 and promotes cancer cell
migration and invasion. Carcinogenesis. 34:58–67. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
de Jonge WJ, Patel HP, Meeussen JVW and
Lenstra TL: Following the tracks: How transcription factor binding
dynamics control transcription. Biophys J. 121:1583–1592. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hong JH and Zhang HG: Transcription
factors involved in the development and prognosis of cardiac
remodeling. Front Pharmacol. 13:8285492022. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Su SC, Lin CW, Yang WE, Fan WL and Yang
SF: The urokinase-type plasminogen activator (uPA) system as a
biomarker and therapeutic target in human malignancies. Expert Opin
Ther Targets. 20:551–566. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mahmood N, Mihalcioiu C and Rabbani SA:
Multifaceted role of the urokinase-type plasminogen activator (uPA)
and its receptor (uPAR): Diagnostic, prognostic, and therapeutic
applications. Front Oncol. 8:242018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nagamine Y, Medcalf RL and Muñoz-Cánoves
P: Transcriptional and posttranscriptional regulation of the
plasminogen activator system. Thromb Haemost. 93:661–675. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li S, Zhang Z, Peng H and Xiao X:
YY1-induced up-regulation of FOXE1 is negatively regulated by
miR-129-5p and contributes to the progression of papillary thyroid
microcarcinoma. Pathol Res Pract. 221:1533372021. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yao W, Yan Q, Du X and Hou J: TNK2-AS1
upregulated by YY1 boosts the course of osteosarcoma through
targeting miR-4319/WDR1. Cancer Sci. 112:893–905. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li F, Shen ZZ, Xiao CM and Sha QK:
YY1-mediated up-regulation of lncRNA LINC00466 facilitates glioma
progression via miR-508/CHEK1. J Gene Med. 23:e32872021. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang Q, Wan M, Shi J, Horita DA, Miller
LD, Kute TE, Kridel SJ, Kulik G and Sui G: Yin Yang 1 promotes
mTORC2-mediated AKT phosphorylation. J Mol Cell Biol. 8:232–243.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wu S, Wang H, Li Y, Xie Y, Huang C, Zhao
H, Miyagishi M and Kasim V: Transcription factor YY1 promotes cell
proliferation by directly activating the pentose phosphate pathway.
Cancer Res. 78:4549–4562. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhai Z, Ren Y, Shu C, Chen D, Liu X, Liang
Y, Li A and Zhou J: JAC1 targets YY1 mediated JWA/p38 MAPK
signaling to inhibit proliferation and induce apoptosis in TNBC.
Cell Death Discov. 8:1692022. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Guan C, Liu L, Zhao Y, Zhang X, Liu G,
Wang H, Gao X, Zhong X and Jiang X: YY1 and eIF4A3 are mediators of
the cell proliferation, migration and invasion in
cholangiocarcinoma promoted by circ-ZNF609 by targeting miR-432-5p
to regulate LRRC1. Aging (Albany NY). 13:25195–25212. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhao L, Li R, Qiu JZ, Yu JB, Cao Y and
Yuan RT: YY1-mediated PTEN dephosphorylation antagonizes IR-induced
DNA repair contributing to tongue squamous cell carcinoma
radiosensitization. Mol Cell Probes. 53:1015772020. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhao L, Li R and Gan YH: Knockdown of Yin
Yang 1 enhances anticancer effects of cisplatin through protein
phosphatase 2A-mediated T308 dephosphorylation of AKT. Cell Death
Dis. 9:7472018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chandrashekar DS, Bashel B, Balasubramanya
SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK and
Varambally S: UALCAN: A portal for facilitating tumor subgroup gene
expression and survival analyses. Neoplasia. 19:649–658. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Bai G, Wei N, Li F, Zhao P, Meng Z, Zou B,
Liu Y, Xu K, Li K, Yao C and Yang P: Function and transcriptional
regulation of TCTN1 in oral squamous cell carcinoma. Oncol Rep.
47:262022. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lynch TR, Xue M, Czerniak CW, Lee C and
Kimble J: Notch-dependent DNA cis-regulatory elements and their
dose-dependent control of C. elegans stem cell self-renewal.
Development. 149:dev2003322022. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yin S, NandyMazumdar M, Paranjapye A and
Harris A: Cross-talk between enhancers, structural elements and
activating transcription factors maintains the 3D architecture and
expression of the CFTR gene. Genomics. 114:1103502022.(Epub ahead
of print). View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Nakayama T, Fukutomi T, Terao Y and
Akagawa K: Syntaxin 1A gene is negatively regulated in a
cell/tissue specific manner by YY1 transcription factor, which
binds to the −183 to −137 promoter region together with gene
silencing factors including histone deacetylase. Biomolecules.
11:1462021. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hou X, Li Y, Huang Y, Zhao H and Gui L:
Adenosine receptor A1-A2a heteromers regulate EAAT2 expression and
glutamate uptake via YY1-induced repression of PPARγ transcription.
PPAR Res. 2020:24102642020. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wei X, Liu F, Jiang X, Xu X, Zhou T and
Kang C: YY1 promotes telomerase activity and laryngeal squamous
cell carcinoma progression through impairment of GAS5-mediated p53
stability. Front Oncol. 11:6924052021. View Article : Google Scholar : PubMed/NCBI
|
